Related Experiment Video
Updated: May 1, 2026
Author Spotlight: Microglia Research on Spinal Cord Heterogeneity and Purification
Published on: September 22, 2023
Administration of microRNA-210 promotes spinal cord regeneration in mice
Satoshi Ujigo1, Naosuke Kamei, Hikmat Hadoush
1*Department of Orthopaedic Surgery, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan †Translational Research Medical Center, Hiroshima University Hospital, Hiroshima, Japan ‡Department of Analysis and Control of Upper Extremity Function, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan; and §Department of Pediatric gastroenterology, University of California San Diego, CA.
Study Design:
Experimental animal study of treatment of spinal cord injury (SCI).
Objective:
To investigate the therapeutic effects of administering microRNA-210 (miR-210) to promote angiogenesis in a mouse SCI model.
Summary Of Background Data:
Despite many previous studies regarding SCI, there is no established treatment in clinical practice. miRNAs have attracted immense attention because of their crucial role in human disease, and they have been proposed as potential new therapeutic targets for SCI.
Methods:
At specific times after administration, mice were analyzed by several methods to examine the distribution of miR-210, histological angiogenesis and neurogenesis, functional recovery from SCI, and the expression levels of target genes of miR-210.
Results:
After injection of miR-210 into the lesion of the injured spinal cord, expression of endogenous miR-210 increased until 6 days after injection. The administration of miR-210 promoted angiogenesis and astrogliosis, and improved functional recovery after SCI compared with the noninjected controls. Furthermore, the area made up of axons and myelin in the spinal cord tissues caudal to the injury site was larger in mice injected with miR-210 than those of the controls. Apoptotic cell death was lower in mice administered miR-210. After administration of miR-210, the expressions of protein-tyrosine phosphate 1B and ephrin-A3, both gene targets of miR-210, were downregulated at the protein level and protein-tyrosine phosphate 1B expression was also downregulated at the transcriptional level.
Conclusion:
MiR-210 might contribute to spinal cord repair by promoting angiogenesis via the inhibition of protein-tyrosine phosphate 1B and ephrin-A3.
Level Of Evidence:
N/A.
Insights
MicroRNA-210 (miR-210) administration promotes spinal cord repair by enhancing blood vessel formation and improving functional recovery in mice with spinal cord injury (SCI). This therapy reduces cell death and supports nerve regeneration, offering a potential new treatment for SCI.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Molecular Biology
Background:
- Spinal cord injury (SCI) lacks effective clinical treatments.
- MicroRNAs (miRNAs) are critical in disease and emerging as therapeutic targets for SCI.
- Investigating novel therapeutic strategies is crucial for SCI management.
Purpose of the Study:
- To evaluate the therapeutic potential of microRNA-210 (miR-210) for promoting angiogenesis in a mouse model of SCI.
- To assess the impact of miR-210 administration on functional recovery and tissue repair after SCI.
Main Methods:
- An experimental animal study involving induced spinal cord injury in mice.
- Administration of miR-210 directly into the injured spinal cord site.
- Analysis of miR-210 distribution, angiogenesis, neurogenesis, functional recovery, and target gene expression.
Main Results:
- miR-210 administration successfully promoted angiogenesis and astrogliosis in the injured spinal cord.
- Significant improvement in functional recovery was observed in mice treated with miR-210 compared to controls.
- Treatment with miR-210 led to increased axonal and myelin preservation and reduced apoptotic cell death.
Conclusions:
- miR-210 shows promise as a therapeutic agent for spinal cord repair.
- The mechanism involves promoting angiogenesis through the inhibition of target genes protein-tyrosine phosphatase 1B and ephrin-A3.
- Further research into miR-210 could lead to novel treatments for SCI.
